Wta. Vandergraaf et al., IN-VITRO AND IN-VIVO STUDIES ON THE ACTION OF BW502U83, AN ARYLMETHYLAMINOPROPANEDIOL, Anti-cancer drugs, 6(1), 1995, pp. 34-39
BW502U83, an arylmethylaminopropanediol (AMAP), showed to be partially
cross resistant in a P-glycoprotein-positive and in a P-glycoprotein-
negative, doxorubicin-resistant cell line, while no cross-resistance w
as noticed in a cisplatin-resistant cell line. Interstrand cross-links
were not observed, but BW502U83 induced extensive DNA strand breaks.
In a feasibility study the effect of intra-arterially BW502U83 was tes
ted. One patient with a hepatocellular carcinoma showed partial remiss
ion and signs of a tumor lysis syndrome, another patient with a hepato
cellular carcinoma improved clinically. A patient with soft tissue sar
coma had stable disease. Transient increase in SGOT, SGPT and LDH were
observed, but no systemic side effects.